Eli Lilly and Company

A health-benefits platform that lets employers set healthcare budgets while employees choose insurance and eligible care to fit their needs.

Circle Pharma discovers macrocycle medicines for cancer and other serious diseases using its MXMO platform, which combines computational, structure-based design with synthetic chemistry to create cell-permeable compounds against difficult protein targets. Its lead programs are investigational and at discovery or preclinical stages.

Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.

Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical.

Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.

Develops neuro-metabolic therapeutics for schizophrenia and ALS

Clinical-stage biopharma developing injectable therapies for hair loss

Develops proximity-guided antibody-drug conjugate therapeutics for cancer and autoimmune disease

Develops durable protein therapeutics via gene therapy for chronic diseases

Developing best-in-class radiopharmaceuticals for cancer treatment